-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 9, the official website of the State Food and Drug Administration announced that the State Food and Drug Administration recently passed the priority review and approval procedure to approve the Class 1 innovative drug Donafenib Tosylate (trade name:) declared by Suzhou Zejing Biopharmaceutical Co.
, Ltd.
Zepson) went public
.
The drug is an innovative drug independently researched and developed by China with independent intellectual property rights.
Donafenib (Donafenib) is a multi-kinase inhibitor class of small molecule anti-tumor drugs
.
The listing of this variety provides a new treatment option for patients with hepatocellular carcinoma